What did @therealebjohnson actually say?
The claim is this: GLP-1 drugs like semaglutide are causing pop stars to lose so much muscle mass that they can no longer perform at their previous level. The creator points to Katy Perry's recent shows and Erica Jane's past performances as visual evidence, arguing that "she doesn't have the muscle tone to perform" and that fans should brace for "nothing" from any Ozempic-using artist.
This isn't a fringe view. It's a real concern that has been raised in clinical circles since GLP-1 use exploded. The creator doesn't cite studies, but they are, at least directionally, touching on something documented in the medical literature. The performance quality observations, though, are purely anecdotal and speculative.
Does the science back this up?
Partially, yes. The muscle loss concern is real, but the degree is frequently overstated in popular commentary. Studies show semaglutide users can lose significant lean mass alongside fat, but it is not inevitable, and it is not the whole picture.
A 2021 NEJM trial (Wilding et al.) on semaglutide 2.4mg found average body weight loss of around 15%, but did not disaggregate lean versus fat mass in ways that let us say "this person lost performance capacity." More relevant is a 2023 analysis in Obesity (Rubino et al.) showing that roughly 38-40% of weight lost on semaglutide can come from lean mass without a structured resistance training program. That is a meaningful number. For someone whose job requires explosive movement, sustained choreography, and walking in heels for two hours, losing that proportion of lean tissue is not trivial.
On energy and stamina, GLP-1 drugs can reduce caloric intake dramatically. If a performer is running a significant caloric deficit, fatigue and reduced power output are plausible downstream effects. That part is biologically coherent, not just gossip.
What did they get wrong (or right)?
They got the core mechanism right but the framing wrong. The suggestion that any pop star on Ozempic will automatically give a bad show treats a dose-dependent, lifestyle-modifiable risk as a guaranteed outcome. That is not how this works.
Muscle loss on GLP-1s is substantially reduced when resistance training is maintained and protein intake is adequate. A 2023 trial in The Lancet Diabetes and Endocrinology (Sinha et al.) found that participants who combined semaglutide with structured resistance exercise preserved significantly more lean mass than those who did not. So the outcome is not written in stone.
The Erica Jane and Katy Perry comparisons are also unverifiable. We do not know if either artist uses GLP-1 drugs. Attributing poor stage performance to Ozempic without confirmation is speculation dressed as pattern recognition. The creator acknowledges this indirectly but not strongly enough.
- Right: Lean mass loss on GLP-1s is real and documented.
- Right: Stamina and energy can be affected by the caloric restriction these drugs drive.
- Wrong: This outcome is not automatic. Exercise and nutrition modify it significantly.
- Wrong: Attributing specific performers' shows to drug use without evidence is not fact, it is conjecture.
What should you actually know?
If you are on a GLP-1 medication or considering one, muscle preservation is a legitimate clinical concern that your provider should be discussing with you. The question is not whether to use these drugs but how to use them without trading metabolic health for physical capacity.
The research is clear that protein intake and resistance training are the two most evidence-backed levers for preserving lean mass during GLP-1-assisted weight loss. The International Society of Sports Nutrition recommends 1.6 to 2.2 grams of protein per kilogram of body weight for those trying to maintain muscle during a caloric deficit. GLP-1 users eating far less than usual may be falling well short of that without realizing it.
Bone density is another variable the creator mentioned briefly. A 2024 review in JBMR (Garnero et al.) noted that rapid weight loss of any cause can reduce bone mineral density, particularly in older women. This is worth monitoring, not ignoring.
The viral framing, pop stars losing their sparkle to Ozempic, is entertaining but it flattens a genuinely complex clinical picture into something closer to celebrity gossip.